arrow
I

Ian M. Thompson

University of Texas Health Science Center at San Antonio
H指数:114
被引数:6.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

INVESTIGATING SHORT TERM (<6 MONTHS) SURVIVORS OF GLIOBLASTOMA - AN ANALYSIS OF THE HISTO-MOL GBM COLLABORATIVE DATABASE.

调查短期(<6个月)胶质母细胞瘤生存者——基于Histology-Molecular GBM Collaborative数据库的分析。

2025-10-010
OAAI
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer

尿液中肿瘤DNA用于分层评估接受阿替利珠单抗治疗的卡介苗难治性非肌层浸润性膀胱癌患者的复发风险

2025-05-220
OAAI
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

体重指数与转移性激素敏感性前列腺癌患者总生存期的相关性:SWOG-1216患者层面数据分析

2024-11-010
PRE
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

3个月和7个月的前列腺特异性抗原水平可作为转移性激素敏感性前列腺癌总生存期的预后指标: SWOG S1216的结果,这是一项雄激素剥夺加Orteronel或比卡鲁胺的3期随机试验

2024-10-012
OA
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
2024-09-013
PRE
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

前列腺切除术中1级组前列腺癌的升级: 前瞻性队列中的种系风险因素

2024-08-191
OA
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel
2024-02-290
PRE
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
2024-02-016
OA